LAG3 and cancer: As our findings show that there is a significant proportion of LAG3+ CD8+ T-cell targeted by ligand LGALS3+ originating from mesenchymal cancer cells, we sought to further explore the link between LGALS3 and EMT to better elucidate how EMT could modulate CD8+ T-cell exhaustion.